Clinicians must balance maintaining lupus nephritis remission against the cumulative harms of long-term immunosuppressive therapy.

Investigators compared adverse events of special interest among patients with systemic lupus erythematosus (SLE) treated with or without add-on belimumab over 5 years.

Lupus nephritis is a serious complication of lupus — and because it doesn’t always cause symptoms right away, it’s important to find it early. Talk to your lupus doctor about getting screened (tested) ...

A regulatory decision is expected by October 2025. The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for obinutuzumab (Gazyva ®) for the ...

Mitochondrial antibody profiling may help identify patients with SLE at increased risk for severe complications, including LN ...

The trial met its primary endpoint showing a significant improvement in complete renal response with obinutuzumab with standard therapy vs standard therapy alone after 76 weeks. Positive topline ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Brad Rovin, MD: ...

Please provide your email address to receive an email when new articles are posted on . HUNTINGTON BEACH, Calif. — Non-nephritis lupus and lupus nephritis may actually be part of a spectrum of ...

An already-approved IV drug significantly reduces the symptoms of lupus, a new clinical trial showed. More than three-quarters of lupus patients taking obinutuzumab (Gazvya) had a significant ...